Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .

Inclusion Criteria

• •Participant must be 18 to 80 years of age inclusive, at the time of signing the informed consent
• •Participants with stable post-stroke Spasticity (ULS) for at least 3 months
• •Participants with Modified Ashworth Scale (MAS) score of at least 2 at elbow flexor or wrist flexor or finger flexor
• •Participants with DAS score of at least 2 on the Principal Target of Treatment (PTT) (one of four functional domains: dressing, hygiene, limb position and pain)
• •Participants who have been stable for at least 1 month prior to study entry in terms of oral antispasticity